RxDoctor Payments Data

Kishwar Husain, MD

Pulmonary Disease · St Augustine, FLNPI 1912000696

Payments from drug & device makers

$1,832in general payments, 2019–2025

Across 75 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$296
  • GSK$149
  • Ambu Inc.$146
  • Amgen$139
  • Boehringer Ingelheim$124
  • Philips North America LLC$123
  • plus $855 from 17 others

What the payments were for

  • Food & beverage$1,81599%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,832 in reported general payments places this provider in the 35th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$345,008
Medicare patients
1,029
Services billed
3,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate84$1,094,392
Trelegy ElliptaFluticasone/Umeclidin/Vilanter215$183,036
Breo ElliptaFluticasone/Vilanterol265$145,640
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$81,276
Spiriva RespimatTiotropium Bromide60$47,809
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$42,240
Ambrisentan13$37,050
Arnuity ElliptaFluticasone Furoate97$28,832
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$23,030
Atrovent HfaIpratropium Bromide17$19,173
Albuterol Sulfate HfaAlbuterol Sulfate384$13,529
Incruse ElliptaUmeclidinium Bromide28$12,635
Combivent RespimatIpratropium/Albuterol Sulfate29$11,991
SymbicortBudesonide/Formoterol Fumarate31$11,817
Spiriva HandihalerTiotropium Bromide12$8,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$124$1,177,222196 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$149$412,382671 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$296$97,133119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →